Loading...
TerrAscend Corp.
TRSSF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.72
$-0.23(-11.79%)

The company's financials show resilient growth, with revenue advancing from $117.90M in Q4 2023 to $74.17M in Q3 2024. Gross profit remained healthy with margins at 49% in Q3 2024 compared to 45% in Q4 2023. Operating income hit $2.45M last quarter, sustaining a consistent 3% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $7.30M. Net income dropped to -$23.15M, while earnings per share reached -$0.08. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan